Eledon Pharmaceuticals, Inc. (ELDN) is a Biotechnology company in the Healthcare sector, currently trading at $3.20. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is ELDN = $5 (+56.3% upside).
Valuation: ELDN trades at a trailing Price-to-Earnings (P/E) of -5.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.11.
Net income is $46M (loss), growing at +12.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $641,000 against $137M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 7.4 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $238M.
Analyst outlook: 4 / 4 analysts rate ELDN as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 62/100 (Pass), Growth 80/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
